iShares MSCI Germany (DAX) vs Novavax Inc — how do they compare? iShares MSCI Germany (DAX) trades at $43.86, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EWG | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $11.19 |
52-Week Low | $38.08 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
EWG trades at $44.04, up 0.39% today, with a bullish technical signal driven by moving averages. Key support and resistance cluster at $44. Recent news highlights European Central Bank rate decisions and German economic policies influencing regional markets.
The outlook is cautiously optimistic given technical strength, but fundamental data is unavailable. Risks include European economic volatility and energy price fluctuations. Investors should assess upcoming financial disclosures for valuation clarity.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →